Pub Date : 2022-09-27DOI: 10.36000/hbt.oh.2022.13.077
{"title":"Promising Findings in Myeloproliferative Neoplasms and AL Amyloidosis","authors":"","doi":"10.36000/hbt.oh.2022.13.077","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.13.077","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"101 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132497930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-27DOI: 10.36000/hbt.oh.2022.13.076
A. Addeo
KRYSTAL-1: Adagrasib demonstrated intracranial activity in previously treated patients with advanced NSCLC harboring a KRASG12C mutation The activity and safety of adagrasib, a covalent and highly selective inhibitor of KRASG12C, have been explored in patients with advanced KRASG12C-mutant solid tumors in the KRYSTAL-1 trial, with positive results previously reported for non-small cell lung cancer (NSCLC) from the phase I/Ib part of the study.1,2 In the registrational phase II cohort, patients with unresectable or metastatic KRASG12C-positive NSCLC, who were previously treated with a programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor in combination or in sequence with chemotherapy, received adagrasib at a dose of 600 mg twice daily.3,4 Of note, patients with treated and stable central nervous system (CNS) metastases were eligible. The primary endpoint was objective response rate (ORR) and secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety.
{"title":"Emerging Treatment Options in Lung Cancer","authors":"A. Addeo","doi":"10.36000/hbt.oh.2022.13.076","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.13.076","url":null,"abstract":"KRYSTAL-1: Adagrasib demonstrated intracranial activity in previously treated patients with advanced NSCLC harboring a KRASG12C mutation The activity and safety of adagrasib, a covalent and highly selective inhibitor of KRASG12C, have been explored in patients with advanced KRASG12C-mutant solid tumors in the KRYSTAL-1 trial, with positive results previously reported for non-small cell lung cancer (NSCLC) from the phase I/Ib part of the study.1,2 In the registrational phase II cohort, patients with unresectable or metastatic KRASG12C-positive NSCLC, who were previously treated with a programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor in combination or in sequence with chemotherapy, received adagrasib at a dose of 600 mg twice daily.3,4 Of note, patients with treated and stable central nervous system (CNS) metastases were eligible. The primary endpoint was objective response rate (ORR) and secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety.","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127119657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-27DOI: 10.36000/hbt.oh.2022.13.080
Dr Kaveh Samii
The phase II 2018-04 study conducted by the Intergroupe Francophone du Myelome (IFM) group confirmed the efficacy and safety of quadruplet induction therapy in high-risk (HR), transplant-eligible (TE), newly diagnosed multiple myeloma patients (NDMM). 1 Previous studies investigating the triplet combination of carfilzomib, lenalidomide and dexamethasone (KRd) demonstrated a high efficacy with a favorable safety profile in TE-NDMM patients. 2 Furthermore, the addition of daratumumab (Dara) to front-line therapy resulted in a deep response and improved progression-free survival (PFS) in TE-NDMM patients, including HR patients. 3,4 The IFM study included TE-NDMM patients (age <66 years) with HR disease defined by cytogenic abnormalities such as translocation (t)(4;14), deletion (del)17p and t(14;16) detected by fluorescence in situ hybridization (FISH). The induction therapy consisted of 6 cycles of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) given over 28 days, followed by stem cell collection and autologous stem cell transplantation (ASCT). Consolidation Dara-KRd was given in 4 cycles followed by a second round of ASCT, and finally, daratumumab and lenalidomide maintenance were adminis - tered over 2 years. The primary objective of this study was the feasibility of this treatment.
Intergroupe Francophone du Myelome (IFM)小组进行的2018-04期II期研究证实了四联体诱导治疗在高危(HR)、符合移植条件(TE)、新诊断的多发性骨髓瘤(NDMM)患者中的有效性和安全性。先前的研究表明，卡非佐米、来那度胺和地塞米松(KRd)三联用药对TE-NDMM患者具有较高的疗效和良好的安全性。此外，在一线治疗中加入达拉单抗(Dara)， TE-NDMM患者(包括HR患者)获得了深度缓解和改善的无进展生存期(PFS)。3,4 IFM研究纳入TE-NDMM患者(年龄<66岁)，伴有HR疾病，通过荧光原位杂交(FISH)检测到细胞遗传学异常，如易位(t)(4;14)、缺失(del)17p和t(14;16)。诱导治疗包括6个周期的达拉单抗、卡非佐米、来那度胺和地塞米松(Dara-KRd)，持续28天，然后进行干细胞收集和自体干细胞移植(ASCT)。巩固达拉- krd在4个周期内给予，随后是第二轮ASCT，最后，达拉单抗和来那度胺维持治疗超过2年。本研究的主要目的是研究这种治疗的可行性。
{"title":"Exciting New Data in Newly Diagnosed Multiple Myeloma","authors":"Dr Kaveh Samii","doi":"10.36000/hbt.oh.2022.13.080","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.13.080","url":null,"abstract":"The phase II 2018-04 study conducted by the Intergroupe Francophone du Myelome (IFM) group confirmed the efficacy and safety of quadruplet induction therapy in high-risk (HR), transplant-eligible (TE), newly diagnosed multiple myeloma patients (NDMM). 1 Previous studies investigating the triplet combination of carfilzomib, lenalidomide and dexamethasone (KRd) demonstrated a high efficacy with a favorable safety profile in TE-NDMM patients. 2 Furthermore, the addition of daratumumab (Dara) to front-line therapy resulted in a deep response and improved progression-free survival (PFS) in TE-NDMM patients, including HR patients. 3,4 The IFM study included TE-NDMM patients (age <66 years) with HR disease defined by cytogenic abnormalities such as translocation (t)(4;14), deletion (del)17p and t(14;16) detected by fluorescence in situ hybridization (FISH). The induction therapy consisted of 6 cycles of daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) given over 28 days, followed by stem cell collection and autologous stem cell transplantation (ASCT). Consolidation Dara-KRd was given in 4 cycles followed by a second round of ASCT, and finally, daratumumab and lenalidomide maintenance were adminis - tered over 2 years. The primary objective of this study was the feasibility of this treatment.","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130514465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.36000/hbt.oh.2022.073
{"title":"Highlights in Prostate Cancer from ASCO GU 2022","authors":"","doi":"10.36000/hbt.oh.2022.073","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.073","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127792219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.36000/hbt.oh.2022.12.075
{"title":"Research for Tomorrow","authors":"","doi":"10.36000/hbt.oh.2022.12.075","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.12.075","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"238 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131512596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.36000/hbt.oh.2022.12.072
{"title":"Highlights in Renal Cell Carcinoma from ASCO GU 2022","authors":"","doi":"10.36000/hbt.oh.2022.12.072","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.12.072","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124234656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.36000/hbt.oh.2022.12.074
{"title":"Geriatric Oncology: Building Clinical Care for Swiss Patients","authors":"","doi":"10.36000/hbt.oh.2022.12.074","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.12.074","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"95 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132797047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-31DOI: 10.36000/hbt.oh.2022.11.062
{"title":"Antibody-Drug Conjugates in Solid Tumors","authors":"","doi":"10.36000/hbt.oh.2022.11.062","DOIUrl":"https://doi.org/10.36000/hbt.oh.2022.11.062","url":null,"abstract":"","PeriodicalId":245688,"journal":{"name":"healthbook TIMES Oncology Hematology","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116619995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：